» Articles » PMID: 33658945

Serum Glycerophospholipid Profile in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Overview
Journal Front Physiol
Date 2021 Mar 4
PMID 33658945
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Studies have shown that glycerophospholipids are involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). This study adopted targeted metabolomic analysis to investigate the changes in serum glycerophospholipids in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and their differential expression in patients with different inflammatory subtypes. Patients with AECOPD admitted between January 2015 and December 2017 were enrolled, and their clinical data were collected. The patients' gender, age, body mass index, and lung function were recorded. Routine blood and induced sputum tests were performed. Liquid chromatography-mass spectrometry was used to detect the serum glycerophospholipid metabolic profiles and to analyze the metabolic profile changes between the acute exacerbation and recovery stages as well as the differences between different inflammatory subtypes. A total of 58 patients were hospitalized for AECOPD, including 49 male patients with a mean age of 74.8 ± 10.0 years. In the metabolic profiles, the expression of lysophosphatidylcholine (LPC) 18:3, lysophosphatidylethanolamine (LPE) 16:1, and phosphatidylinositol (PI) 32:1 was significantly reduced in the acute exacerbation stage compared to the recovery stage ( < 0.05). The three glycerophospholipids were used to plot the receiver operating characteristic curves to predict the acute exacerbation/recovery stage, and the areas under the curves were all above 70%. There were no differential metabolites between the two groups of patients with blood eosinophil percentage (EOS%) ≥2% and <2% at exacerbation. The expression of LPC 18:3, LPE 16:1, and PI 32:1 was significantly reduced in the acute exacerbation stage compared to the recovery stage in the inflammatory subtype with blood EOS <2% ( < 0.05). Abnormalities in the metabolism of glycerophospholipids may be involved in the onset of AECOPD, especially in the non-eosinophilic subtype.

Citing Articles

Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.

Shi Y, Yang J, Tian T, Li S, Xie Y Front Microbiol. 2024; 15:1487393.

PMID: 39483760 PMC: 11526122. DOI: 10.3389/fmicb.2024.1487393.


Causal relationship between Lipdome and Chronic Obstructive Pulmonary Disease and Asthma: Mendelian randomization.

Wu Q, Fu J, Zhang C, Liu Z, Shi J, Feng Z 3 Biotech. 2024; 14(10):249.

PMID: 39328502 PMC: 11424600. DOI: 10.1007/s13205-024-04071-x.


LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T-cells.

Aili A, Wang Y, Shang Y, Zhang L, Liu H, Li Z Eur Respir J. 2024; 64(6).

PMID: 39147414 PMC: 11618814. DOI: 10.1183/13993003.01752-2023.


The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease.

Zhou Q, Chen Y, Liang Y, Sun Y Metabolites. 2024; 14(6).

PMID: 38921452 PMC: 11205356. DOI: 10.3390/metabo14060317.


Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype.

Ding H, Wang H, Wu D, Zhou F, Zhu J, Tong J Mol Med Rep. 2024; 30(2).

PMID: 38873983 PMC: 11200052. DOI: 10.3892/mmr.2024.13261.


References
1.
Sevastou I, Kaffe E, Mouratis M, Aidinis V . Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 2012; 1831(1):42-60. DOI: 10.1016/j.bbalip.2012.07.019. View

2.
Drzazga A, Sowinska A, Koziolkiewicz M . Lysophosphatidylcholine and lysophosphatidylinosiol--novel promissing signaling molecules and their possible therapeutic activity. Acta Pol Pharm. 2015; 71(6):887-99. View

3.
Eto M, Shindou H, Yamamoto S, Tamura-Nakano M, Shimizu T . Lysophosphatidylethanolamine acyltransferase 2 (LPEAT2) incorporates DHA into phospholipids and has possible functions for fatty acid-induced cell death. Biochem Biophys Res Commun. 2020; 526(1):246-252. DOI: 10.1016/j.bbrc.2020.03.074. View

4.
Wang B, Tontonoz P . Phospholipid Remodeling in Physiology and Disease. Annu Rev Physiol. 2018; 81:165-188. PMC: 7008953. DOI: 10.1146/annurev-physiol-020518-114444. View

5.
Murakami M, Taketomi Y, Miki Y, Sato H, Yamamoto K, Lambeau G . Emerging roles of secreted phospholipase A2 enzymes: the 3rd edition. Biochimie. 2014; 107 Pt A:105-13. DOI: 10.1016/j.biochi.2014.09.003. View